PHARMACEUTICAL COMPANY AstraZeneca will pay $1.1bn to resolve an ongoing transfer pricing dispute over its US business.
The UK-Swedish based firm will pay the $1.1bn net costs to US tax authorities to cover transfer pricing arrangements over a 13-year period from 2002 to the end of 2014, it announced today. It had already announced in February that it will pay £505m to settle a dispute with HM Revenue & Customs.
“AstraZeneca had provided in its accounts for the outcome of these issues, at the heart of which are complex transfer pricing considerations that have taken many years to resolve,” the group said.
It also said that the group’s effective tax rate for 2011 is expected to be approximately six percentage points lower than the previous guidance of 27%, at around 21%.
HMRC is continuing to ramp up the number of raids on premises it carries out as part of criminal investigations, searching 761 properties in the last year
Lord Howard Leigh of Hurley discusses the government’s initiatives to mitigate tax avoidance and evasion
Top 50+50: Demand for tax advisory services remains high, but fee pressure is expected in relation to compliance services
The demand for tax advisory services remains high and this looks to continue; but fee pressure is expected in relation to compliance services as the “Making Tax Digital” initiative is rolled out,
While some resistance to change is to be expected, the degree of controversy surrounding HMRC's Making Tax Digital proposals has surprised the government